Gottlieb's Complex Generics Remarks Could Signal (Some) Increased Flexibility
Executive Summary
US FDA commissioner spoke to agency scientists and researchers at Generic Drug Science Day, where he discussed future plans to facilitate complex generic development.
You may also be interested in...
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
‘Better informed patients,’ ‘drug competition,’ ‘biosimilar innovation’ – as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
‘Better informed patients,’ ‘drug competition,’ ‘biosimilar innovation’ – as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.